Boston Trust Walden’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
Other funds holding HALO
Boston Trust Walden's HALO Position: Q3 2026 in Review
Boston Trust Walden reduced its Halozyme (HALO) stake by 4.4% in Q3 2026, selling an estimated $4.56M and leaving 1,035,813 shares worth $114M. The position accounts for 0.92% of the portfolio, ranked #17.
Boston Trust Walden first reported a position in HALO in Q2 2024 and has held it in 10 quarters since. 771 funds tracked by Wall St. Rank hold HALO as of Q3 2026.
- Boston Trust Walden held 1,035,813 shares of Halozyme worth $114M as of Q3 2026.
- Boston Trust Walden sold 47,249 Halozyme shares in Q3 2026, an estimated $4.56M.
- Halozyme made up 0.92% of Boston Trust Walden's portfolio in Q3 2026, its #17 holding.
- Boston Trust Walden first reported a position in Halozyme in Q2 2024 and has held it in 10 quarters since.
- 771 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.
Based on Boston Trust Walden's 13F filing for Q3 2026, filed 30 Oct 2026.